Answer:
The process of the formation of Urine starts when the blood enters the kidney and is filtered by the nephrons to separate the water from the larger elements that compound it like blood cells and proteins. Then, they go to the blood, and the elements that passed the filtration membrane go to the renal tubule to be moved to the bladder or be reabsorbed in case they are necessary for the body.
Explanation:
The Urine creation process starts with the blood entering the nephron in the kidneys. Then it is filtrated blocking blood cells and large proteins, making only water and smaller elements pass the filtration membrane. Then, cells and proteins, as well as the elements that couldn't pass the filtration membrane, go back to the bloodstream. While the elements that passed the filtration membrane go to the nephron to enter the renal tubule. In this tube some of the components that can still be used by the body are reabsorbed, the rest continues its journey to the bladder.
The answer is true because walking does not affect the environment
Answer:
[4]
1. Nasopharynx
2. Trachea
3. Lung
4. Diaphragm
Explanation:
Sorry don't know anything about plants.
Yes, it is true that Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis.
Enhancer of zeste homolog 2 (EZH2), a key histone methyltransferase and EMT inducer, is overexpressed in diverse carcinomas, including breast cancer.
However, the molecular mechanisms of EZH2 dysregulation in cancers are still largely unknown. Here, we discover that EZH2 is asymmetrically dimethylated at R342 (meR342-EZH2) by PRMT1.
meR342-EZH2 was found to inhibit the CDK1-mediated phosphorylation of EZH2 at T345 and T487, thereby attenuating EZH2 ubiquitylation mediated by the E3 ligase TRAF6.
We also demonstrate that meR342-EZH2 resulted in a decrease in EZH2 target gene expression, but an increase in breast cancer cell EMT, invasion and metastasis.
Moreover, we confirm the positive correlations among PRMT1, meR342-EZH2 and EZH2 expression in the breast cancer tissues. Finally, we report that high expression levels of meR342-EZH2 predict a poor clinical outcome in breast cancer patients.
Our findings may provide a novel diagnostic target and promising therapeutic target for breast cancer metastasis.
Learn more about breast cancer here : brainly.com/question/6747562
#SPJ4
